In a patient with an upper gastrointestinal (GI) bleed and an elevated international normalized ratio (INR), should fresh frozen plasma (FFP) be given, and what is the appropriate dose?

FFP Should Generally Be Avoided in Upper GI Bleeding with Elevated INR

In patients with upper gastrointestinal bleeding and elevated INR, fresh frozen plasma (FFP) should NOT be routinely administered, as it does not improve outcomes and may cause harm. If reversal is absolutely necessary for severe coagulopathy, prothrombin complex concentrate (PCC) is preferred over FFP 1, 2.

Key Recommendations by Clinical Scenario

For Warfarin-Associated Coagulopathy

• Do not give FFP routinely 2
• Do not give vitamin K routinely 2
• If reversal is deemed essential (severe bleeding with hemodynamic instability), use 4-factor PCC instead of FFP 1, 2
• Do not delay endoscopy to correct INR 1

For DOAC-Associated Bleeding

• Do not give PCC 2
• Do not give specific reversal agents (idarucizumab for dabigatran, andexanet alfa for rivaroxaban/apixaban) 2
• DOACs have short half-lives (8-12 hours) and resolve spontaneously 1

For Portal Hypertension/Variceal Bleeding

• Strongly avoid FFP transfusion - this population shows particularly poor outcomes with FFP 3, 4
• Do not give routine platelet transfusions even with thrombocytopenia 3

Evidence Supporting Avoidance of FFP

Harm from FFP Transfusion

The most recent and highest quality evidence demonstrates significant harm from pre-endoscopic FFP in patients with mild coagulopathy (INR 1.5-2.5) 4:

• 5.3-fold increased in-hospital mortality (aOR 5.36)
• 3.9-fold increased pulmonary edema (aOR 3.85)
• 2.7-fold increased 30-day mortality (aOR 2.69)
• These associations were strongest in variceal bleeding patients

Ineffectiveness of FFP

• FFP fails to normalize INR in most patients with mild elevations 4, 5, 6
• Only 12-25% of patients achieve predicted INR correction 7
• INR changes minimally with FFP when baseline INR <1.7 5
• At INR 1.5-2.5, FFP transfusion showed no reduction in bleeding complications despite persistent elevated INR 6

Procedural Delays

• FFP transfusion causes significant delays to lifesaving endoscopy (median 25.3 vs 16.4 hours) 6
• Early endoscopy is beneficial and should not be delayed for coagulopathy correction 1

When to Consider Reversal (Rare Circumstances)

If reversal is absolutely necessary (massive hemorrhage with hemodynamic collapse):

• Use 4-factor PCC, not FFP 1, 2
• PCC demonstrates superior INR correction compared to FFP 1
• Accept that rapid reversal carries thrombotic risk 1

Critical Pitfalls to Avoid

1. Do not use INR as a bleeding risk predictor - INR correlates poorly with actual bleeding risk in liver disease and GI bleeding 8
2. Do not transfuse "2 units of FFP" - this common practice is insufficient and arbitrary 9
3. Do not assume coagulopathy requires correction - patients with CLD have rebalanced hemostasis 8
4. Do not delay endoscopy - early endoscopy (within 24 hours) is safe even with elevated INR 1

Practical Algorithm

For INR 1.5-2.5 (mild elevation):

• Proceed directly to endoscopy
• No FFP, no reversal agents
• Transfuse RBCs as needed for anemia

For INR >2.5 (moderate elevation):

• Still proceed to endoscopy without delay 1
• Consider PCC only if massive hemorrhage with shock
• Avoid FFP

For warfarin patients:

• Interrupt warfarin
• Do not give vitamin K or FFP routinely 2
• PCC only for life-threatening bleeding

For DOAC patients:

• Interrupt medication
• Supportive care (shorter half-life than warfarin)
• No reversal agents 2

The evidence strongly supports a restrictive, selective approach that prioritizes early endoscopy over coagulation correction, as FFP transfusion increases mortality and complications without improving hemostasis 4, 2.